The Washington PostNovember 10, 2026Regulatory
FDA tells GLP-1 makers to warn of potential vision loss side effect
Reported by The Washington Post. Read the original →
What the story says
The FDA has instructed manufacturers of GLP-1 medications to include warnings about a potential side effect related to vision loss.
Summarised by a model from The Washington Post's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
GLP-1 and incretin therapiesclass
14 compounds tracked · 373 studies on file · 163 in humans
What the headline doesn't tell you
- This story is about a class — GLP-1 and incretin therapies — rather than one compound. We track 14 compounds in it, holding 373 studies between them, 163 in humans.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.